221 related articles for article (PubMed ID: 25131421)
1. Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.
Heselmeyer-Haddad KM; Berroa Garcia LY; Bradley A; Hernandez L; Hu Y; Habermann JK; Dumke C; Thorns C; Perner S; Pestova E; Burke C; Chowdhury SA; Schwartz R; Schäffer AA; Paris PL; Ried T
Am J Pathol; 2014 Oct; 184(10):2671-86. PubMed ID: 25131421
[TBL] [Abstract][Full Text] [Related]
2. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
3. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
[TBL] [Abstract][Full Text] [Related]
5. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
6. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
7. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
[TBL] [Abstract][Full Text] [Related]
8. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
9. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
[TBL] [Abstract][Full Text] [Related]
11. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
12. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
Krohn A; Freudenthaler F; Harasimowicz S; Kluth M; Fuchs S; Burkhardt L; Stahl P; C Tsourlakis M; Bauer M; Tennstedt P; Graefen M; Steurer S; Sirma H; Sauter G; Schlomm T; Simon R; Minner S
Mod Pathol; 2014 Dec; 27(12):1612-20. PubMed ID: 24762546
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
[TBL] [Abstract][Full Text] [Related]
15. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
16. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
17. Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer.
Fallahabadi ZR; Noori Daloii MR; Mahdian R; Behjati F; Shokrgozar MA; Abolhasani M; Asgari M; Shahrokh H
Gene; 2016 Jan; 575(2 Pt 3):755-60. PubMed ID: 26424596
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
Albadine R; Latour M; Toubaji A; Haffner M; Isaacs WB; A Platz E; Meeker AK; Demarzo AM; Epstein JI; Netto GJ
Mod Pathol; 2009 Nov; 22(11):1415-22. PubMed ID: 19734849
[TBL] [Abstract][Full Text] [Related]
19. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
